LungLife AI, Inc.
(the "Company" or "LungLife")
Enrolment completed for pivotal validation study of LungLB®
Company to work with clinical sites to ensure data quality ahead of analysis and readout
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal validation study of LungLB®. Since February 2022, 425 study participants have been enrolled from seventeen sites across the United States from leading academic medical centres and Veterans Affairs hospitals.
The Company is now focused on preparing the data for detailed analysis, including working with each clinical site to finalise monitoring of study data before it is unblinded. Monitoring ensures complete, accurate, and high-quality information will be received for all participants in the study prior to final analyses and results interpretation. In line with expectations, the Company estimates this process will take between 3-4 months, at which point the study results are expected to be known. Following this, the Company will seek to publish the study findings in a peer-reviewed medical journal.
Commenting, Paul Pagano, Chief Executive Officer of LungLife, said: "Completing enrolment is a considerable milestone along the path to commercialisation, and we are pleased that we continue to remain on-track with the timeline set out at IPO. We would like to thank our clinical investigators and their teams, and importantly the study participants, for taking part in our trial and for their continued support with study close-out."
For further information please contact:
| LungLife AI, Inc. | |
| Paul Pagano, CEO | Via Walbrook PR |
| David Anderson, CFO |
|
|
|
|
| Investec Bank plc (Nominated Adviser & Broker) | Tel: +44 (0)20 7597 5970 |
| Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
| | |
| Goodbody (Joint Broker) | Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420 |
| Tom Nicholson / Stephen Kane |
|
|
|
|
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
| Stephanie Cuthbert / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.